pricing

NHS weight-loss drug rollout called unambitious by MPs

The Commons Health and Social Care Committee says about 6% of eligible people in England will get Mounjaro on the NHS in three years and wants the pace reviewed

A printed report and pen on a desk, representing a parliamentary committee publication

MPs have called for an urgent review of how the NHS in England makes weight-loss medicines available, saying the current plan will reach only a small fraction of the people who qualify. The Commons Health and Social Care Committee report, covered on 23 October 2026, described the rollout of tirzepatide, sold as Mounjaro, as unambitious. On Hello Rayo's account of the report, the committee found that around 6% of eligible people will receive the drug on the NHS during the first three years, against an NHS estimate of 2.8 million eligible patients in England. The Pharmacist reported that the slow rollout has created "a 'two-tier system' determined by people's ability to pay", with many people turning to private providers instead. NICE recommended tirzepatide for managing overweight and obesity in June 2024, then agreed to a phased rollout at NHS England's request on cost grounds. The predicted cost was £15.2 billion over five years if everyone eligible came forward in the first year.

What the committee recommended

The report asks the government to hold a summit on GLP-1 access with a range of providers and health professionals, and to give regulated digital providers and pharmacies secure access to patient records so they can see and record that someone is already receiving one of these medicines. It also calls for a timetable for expanding shared records with privacy safeguards, a review of whether the MHRA is sufficiently resourced to address the illegal trade, and wider public warning about unregulated sources. Of the regulator, the report said: "The MHRA seems to be playing catch up, rather than proactively addressing this challenge." Layla Moran, who chairs the committee, said: "Weight-loss drugs have been a positive innovation, but they remain out of reach for those who can't afford them."

What this means in practice

Nothing in the report concerns food supplements and the committee made no findings about them. The change it points at is administrative. It asks whether a pharmacy or a regulated digital provider can see that a patient is already prescribed one of these medicines before supplying anything. Prescription-only medicines are not sold on perqen.co.uk. Our full product catalogue is food supplements, which are not a treatment for obesity and are not an alternative to anything a prescriber has recommended. The NHS England rollout and this report cover England, and obesity care pathways are devolved, so Scotland, Wales and Northern Ireland set their own arrangements.

This article reports published news and research and is for information only. Food supplements are not a substitute for a varied diet or medical care, and no product mentioned is intended to diagnose, treat, cure or prevent any disease. Speak to your GP or pharmacist before changing what you take, especially if you are pregnant, breastfeeding, or taking prescribed medicines.

Sources